SNS 201
Alternative Names: SNS-201Latest Information Update: 05 Mar 2024
At a glance
- Originator Sensei Biotherapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD28 antigen stimulants; T lymphocyte stimulants; VISTA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 07 Feb 2024 Early research in Solid tumours in USA (Parenteral) (Sensei Biotherapeutics pipeline, February 2024)
- 31 Jan 2024 Sensi Biotherapeutics pauses IND-enabling preclinical studies of SNS 201, SNS 102 and SNS 103 to realign its resources to fully support the phase I/II trial of SNS 101
- 31 Jan 2023 Preclinical trials in Solid tumours in USA (Parenteral), prior to January 2023